Albright Hereditary Osteodystrophy Clinical Trial
Official title:
Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study
The investigators would like to learn more about the metabolic consequences of pseudohypoparathyroidism type 1a in children, adolescents and adults with this condition. People with pseudohypoparathyroidism 1a are at risk for development of obesity. To better understand the cause of overweight or obesity, investigators are measuring body composition and resting energy expenditure (REE), which is the amount of calories burned while completely at rest. The investigators also want to determine the amount of body fat.
Pseudohypoparathyroidism 1a (PHP1a) is a disorder that is associated with many endocrine
problems. People with PHP1a are at risk for the development of obesity. The objective of the
study will help determine if obesity is related to abnormalities energy expenditure, meaning
that people with PHP1a may not burn as many calories while at rest as those without the
disorder.
In order to further evaluate obesity in PHP1a, investigators are planning to measure resting
energy expenditure (REE), which is the amount of calories burned while completely at rest.
Investigators will also evaluate body composition by looking at measures of growth and
development and determining the amount of body fat using dual energy x-ray absorptiometry
(DXA) as well as blood and urine biologic markers of obesity. The investigators plan to
evaluate people with PHP1a at all weights.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03029429 -
Theophylline Treatment for Pseudohypoparathyroidism
|
Phase 2 | |
Enrolling by invitation |
NCT04240821 -
Theophylline for Treatment of Pseudohypoparathyroidism
|
Phase 2 | |
Completed |
NCT02463409 -
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
|
Phase 2 | |
Terminated |
NCT03761290 -
Glucose Homeostasis in Pseudohypoparathyroidism
|
||
Recruiting |
NCT04551170 -
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
|
Phase 2 | |
Recruiting |
NCT00209235 -
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
|
N/A | |
Completed |
NCT02411461 -
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
|